L3VLUP
ProSign in

DYN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DYNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DYN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterDYNVRTX
Q3 20203 holders, $11m31 holders, $21.9bn
Q4 20201 holders, $10m30 holders, $18.4bn
Q1 20211 holders, $5.9m31 holders, $15.4bn
Q2 20212 holders, $19m30 holders, $12.7bn
Q3 20212 holders, $17m35 holders, $10.1bn
Q4 20212 holders, $21m28 holders, $12.4bn
Q1 20222 holders, $26m23 holders, $16.1bn
Q2 20221 holders, $4.6m25 holders, $18.1bn
Q3 20221 holders, $19m22 holders, $18.4bn
Q4 20222 holders, $17m28 holders, $18.4bn
Q1 20231 holders, $432k26 holders, $21.4bn
Q2 20231 holders, $4.3m27 holders, $24.7bn
Q3 20231 holders, $3.0m33 holders, $24.3bn
Q4 20231 holders, $5.8m32 holders, $28.6bn
Q1 20244 holders, $123m31 holders, $29.8bn
Q2 20245 holders, $433m29 holders, $33.4bn
Q3 20245 holders, $392m27 holders, $33.5bn
Q4 20246 holders, $287m26 holders, $28.5bn
Q1 20255 holders, $141m21 holders, $35.4bn
Q2 20253 holders, $94m21 holders, $32.3bn
Q3 20255 holders, $228m22 holders, $25.9bn
Q4 20255 holders, $291m26 holders, $31.8bn
Q1 20265 holders, $264m25 holders, $31.8bn
Q2 20263 holders, $288m26 holders, $34.6bn
DYN

Dyne Therapeutics Inc

Holders
3
Reported value
$94m
Buyers
1
Sellers
1

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 23 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DYN (2)

Farallon Capital Management LLC, PDT Partners LLC

Only VRTX (20)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →